US Food and Drug Administration officials are ready consider novel ideas for using real-world evidence to support labeling changes or meet postmarket requirements, but in return program participants must allow some public discussion of them.
Agency officials on 19 October announced the launch of the Advancing Real-World Evidence (RWE) Program, which is among the commitments...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?